AP30663
Cardioversion of Atrial Fibrillation
Phase 2Active
Key Facts
About Acesion Pharma
Acesion Pharma is a clinical-stage biotech company developing first-in-class therapies for atrial fibrillation by targeting the SK ion channel, a novel antiarrhythmic mechanism. The company has advanced its lead candidate, AP30663, through Phase 2 and has initiated a Phase 2 trial for a next-generation candidate, AP31969. Backed by a world-class scientific advisory board and private investment, Acesion aims to address the significant unmet need for safer, more effective cardioversion and rhythm control treatments in a large and growing market.
View full company profile